4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis

Planegg-Martinsried, Germany, (PresseBox) - 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA. This compared vidofludimus, an oral inhibitor of DHODH and pro-inflammatory cytokines (including IL-17A and IL-17F as well as INF-gamma), in rheumatoid arthritis patients on methotrexate background therapy versus methotrexate monotherapy over a treatment period of 13 weeks.

ACR20 response improvement of the 35 mg vidofludimus group compared to placebo was statistically significant (p<0.05) at week 2 (16.7% vs. 6.9%) and week 8 (46.7% vs. 31.9%), however, vidofludimus missed the primary endpoint of significantly improving ACR20 response at week 13 (50.0% vs. 44.8%). Time to ACR20 response was significantly (p<0.05) shorter in the vidofludimus group compared to placebo (median 56 days vs. 92 days). The patient group treated with vidofludimus also reported higher ACR50 (25.8% vs. 17.2%) and ACR70 (12.5% vs. 6%) response rates compared to placebo at week 13.

Overall, vidofludimus was safe and well tolerated. No obvious differences in the adverse event rate between the vidofludimus and placebo group were observed. In particular, there were no relevant increases of diarrhea, neutropenia, anemia, hypertension, cholesterol or liver enzyme levels. Only one serious adverse event was reported in the vidofludimus group which was judged as not related to vidofludimus. No deaths occurred. These safety results were consistent with previous Phase IIa trial results in RA and inflammatory bowel disease patients 4SC will continue to analyse the current data set and the new data that will become available in the weeks ahead. The Company will use this data and data from previous trials to continue its discussions with potential partners. Meanwhile 4SC's future development of vidofludimus will be focused on inflammatory bowel disease (IBD) and, potentially, other autoimmune indications such as lupus and psoriasis.

4SC will continue to analyse the current data set and the new data that will become available in the weeks ahead. The Company will use this data and data from previous trials to continue its discussions with potential partners. Meanwhile 4SC's future development of vidofludimus will be focused on inflammatory bowel disease (IBD) and, potentially, other autoimmune indications such as lupus and psoriasis.

About Vidofludimus

Vidofludimus is a novel, orally administered small molecule for the treatment of autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease. The therapeutic efficacy of vidofludimus is based on a dual principle. Vidofludimus inhibits the expression of selected pro-inflammatory cytokines, including interleukin-17 (IL-17A and IL-17F) and INF-gamma that have crucial pathogenic roles in a variety of autoimmune diseases. Vidofludimus also inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme of the pyrimidine biosynthesis, thereby halting the proliferation of activated T and B cells which are involved in the pathology of autoimmune disorders. Vidofludimus has completed a positive Phase IIa trial in inflammatory bowel disease. In addition, various preclinical models demonstrate the application options of vidofludimus in further autoimmune indications such as lupus, psoriasis, multiple sclerosis and transplant rejection.

About the COMPONENT study

The COMPONENT study is a randomised, double-blind, placebo-controlled, multi-centre, international Phase IIb study evaluating the efficacy of vidofludimus with methotrexate, compared to methotrexate alone, in rheumatoid arthritis (RA) patients. The primary endpoint of this study is the estimation of ACR20, secondary endpoints are ACR50, ACR70, DAS28, safety parameters and pharmacokinetics. The trial enrolled 241 patients in two study arms across 28 sites in Poland, Romania, Bulgaria and Czech Republic. In the first study arm patients received 35mg of vidofludimus given orally once-daily plus methotrexate, in the second study arm patients received placebo plus methotrexate. The study duration was 13 weeks and eligible patients must have had active RA, have received weekly doses of MTX (10 25 mg/week) for a minimum of 3 months prior to Day 1 dosing, and have received a stable MTX dose for at least 6 weeks prior to Day 1 dosing.

More information about the COMPONENT study can be found on www.clinicaltrials.gov (Identifier NCT01010581).

4SC AG

4SC (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for the treatment of diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.